Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
UCLM802 Cell InjectionBIOLOGICAL
Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
Study Locations
No locations listed.